11/14/2024 | Julian Upton | 2 min read
Fred Guerard, PharmD, CEO of Opthea, outlines the clinical development of sozinibercept in combination with standard-of-care anti-VEGF-A therapies
Register to access our FREE online portfolio, request the magazine in print and manage your preferences.
Register
Access All Areas: Recognizing Global Education Impact 2024
POAG Preferences
The Future-Ready Surgeon
The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: